The relationship between N-terminal prosomatostatin, all-cause and cardiovascular mortality in patients with type 2 diabetes mellitus (ZODIAC-35)

BMC Endocrine Disorders

Nanne Kleefstra¹  Stephan JL Bakker³  Henk JG Bilo³  Klaas H Groenier⁴  Joachim Struck⁵  Larissa van Essen²  Gijs WD Landman²  Peter R van Dijk² 

[1]Langerhans Medical Research group, Zwolle, The Netherlands

[2]Isala, Diabetes Centre, Zwolle, 8000 G.K, The Netherlands

[3]Department of Internal Medicine, University Medical Center Groningen and University of Groningen, Groningen, The Netherlands

[4]Department of General Practice, University Medical Center Groningen and University of Groningen, Groningen, The Netherlands

[5]Sphingotec GmbH, Hennigsdorf, Germany

关键词: Mortality;    N-terminal prosomatostatin;    Somatostatin;    Type 2 diabetes mellitus;   

Others  :  1172374
DOI  :  10.1186/s12902-015-0009-2

 received in 2014-06-19, accepted in 2015-03-13,  发布年份 2015

【 摘 要 】

Background

The hormone somatostatin inhibits growth hormone release from the pituitary gland and is theoretically linked to diabetes and diabetes related complications. This study aimed to investigate the relationship between levels of the stable somatostatin precursor, N-terminal prosomatostatin (NT-proSST), with mortality in type 2 diabetes (T2DM) patients.

Methods

In 1,326 T2DM outpatients, participating in this ZODIAC prospective cohort study, Cox proportional hazards models were used to investigate the independent relationship between plasma NT-proSST concentrations with all-cause and cardiovascular mortality.

Results

Median concentration of NT-proSST was 592 [IQR 450–783] pmol/L. During follow-up for 6 [3–10] years, 413 (31%) patients died, of which 176 deaths (43%) were attributable to cardiovascular causes. The age and sex adjusted hazard ratios (HRs) for all-cause and cardiovascular mortality were 1.48 (95%CI 1.14 - 1.93) and 2.21 (95%CI 1.49 - 3.28). However, after further adjustment for cardiovascular risk factors there was no independent association of log NT-proSST with mortality, which was almost entirely attributable to adjustment for serum creatinine. There were no significant differences in Harrell’s C statistics to predict mortality for the models with and without NT-proSST: both 0.79 (95%CI 0.77 – 0.82) and 0.81 (95%CI 0.77 – 0.84).

Conclusions

NT-proSST is unsuitable as a biomarker for cardiovascular and all-cause mortality in stable outpatients with T2DM.

【 授权许可】

   
2015 van Dijk et al.; licensee BioMed Cenrtral.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Guillemin R, Gerich JE: Somatostatin: physiological and clinical significance. Annu Rev Med 1976, 27:379-88.
• [2]Yamada T, Soll AH, Park J, Elashoff J: Autonomic regulation of somatostatin release: studies with primary cultures of canine fundic mucosal cells. Am J Physiol 1984, 247(5 Pt 1):G567-73.
• [3]Ensinck JW, Laschansky EC, Vogel RE, Simonowitz DA, Roos BA, Francis BH: Circulating prosomatostatin-derived peptides. Differential responses to food ingestion. J Clin Invest 1989, 83:1580-9.
• [4]Chiba T, Taminato T, Kadowaki S, Goto Y, Mori K, Seino Y, et al.: Effects of [Asu1,7]-eel calcitonin on gastric somatostatin and gastrin release. Gut 1980, 21:94-7.
• [5]Siler TM, VandenBerg G, Yen SS, Brazeau P, Vale W, Guillemin R: Inhibition of growth hormone release in humans by somatostatin. J Clin Endocrinol Metab 1973, 37:632-4.
• [6]Reisine T: Somatostatin. Cell Mol Neurobiol 1995, 15:597-614.
• [7]Raptis S, Schlegel W, Lehmann E, Dollinger HC, Zoupas C: Effects of somatostatin on the exocrine pancreas and the release of duodenal hormones. Metabolism 1978, 27(9 Suppl 1):1321-8.
• [8]Creutzfeldt W, Arnold R: Somatostatin and the stomach: exocrine and endocrine aspects. Metabolism 1978, 27(9 Suppl 1):1309-15.
• [9]Gerich JE: Somatostatin and diabetes. Am J Med 1981, 70:619-26.
• [10]Gerich JE, Lorenzi M, Hane S, Gustafson G, Guillemin R, Forsham PH: Evidence for a physiologic role of pancreatic glucagon in human glucose homeostasis: studies with somatostatin. Metabolism 1975, 24:175-82.
• [11]Ezzat VA, Duncan ER, Wheatcroft SB, Kearney MT: The role of IGF-I and its binding proteins in the development of type 2 diabetes and cardiovascular disease. Diabetes Obes Metab 2008, 10:198-211.
• [12]Wallander M, Brismar K, Ohrvik J, Rydén L, Norhammar A: Insulin-like growth factor I: a predictor of long-term glucose abnormalities in patients with acute myocardial infarction. Diabetologia 2006, 49:2247-55.
• [13]Rehman HU: The role of growth hormone in the pathogenesis of vascular complications of diabetes mellitus. Am J Med Sci 2000, 320:128-34.
• [14]Sheppard M, Shapiro B, Pimstone B, Kronheim S, Berelowitz M, Gregory M: Metabolic clearance and plasma half-disappearance time of exogenous somatostatin in man. J Clin Endocrinol Metab 1979, 48:50-3.
• [15]Hildebrand P, Ensinck JW, Buettiker J, Drewe J, Burckhardt B, Gyr K, et al.: Circulating somatostatin-28 is not a physiologic regulator of gastric acid production in man. Eur J Clin Invest 1994, 24:50-6.
• [16]Rabbani SN, Patel YC: Peptides derived by processing of rat prosomatostatin near the amino-terminus: characterization, tissue distribution, and release. Endocrinology 1990, 126:2054-61.
• [17]Bersani M, Thim L, Baldissera FG, Holst JJ: Prosomatostatin 1–64 is a major product of somatostatin gene expression in pancreas and gut. J Biol Chem 1989, 264:10633-6.
• [18]Mouchantaf R, Watt HL, Sulea T, Seidah NG, Alturaihi H, Patel YC, et al.: Prosomatostatin is proteolytically processed at the amino terminal segment by subtilase SKI-1. Regul Pept 2004, 120:133-40.
• [19]Slagman A, Searle J, von Recum J, Holert F, Ziera T, Struck J, et al.: Prosomatostatin as a marker for acute heart failure in unselected patients in the emergency department. Clin Chem 2013, 59:B-238.
• [20]Ubink-Veltmaat LJ, Bilo HJG, Groenier KH, Rischen RO, Meyboom-de Jong B: Shared care with task delegation to nurses for type 2 diabetes: prospective observational study. Neth J Med 2005, 63:103-10.
• [21]Ubink-Veltmaat LJ, Bilo HJG, Groenier KH, Houweling ST, Rischen RO, Meyboom-de Jong B: Prevalence, incidence and mortality of type 2 diabetes mellitus revisited: a prospective population-based study in The Netherlands (ZODIAC-1). Eur J Epidemiol 2003, 18:793-800.
• [22]Lutgers HL, Gerrits EG, Graaff R, Links TP, Sluiter WJ, Gans RO, et al.: Skin autofluorescence provides additional information to the UK Prospective Diabetes Study (UKPDS) risk score for the estimation of cardiovascular prognosis in type 2 diabetes mellitus. Diabetologia 2009, 52:789-97.
• [23]Rutten GEHM, Verhoeven S, Heine RJ, de Grauw WJC, Cromme PVM, Reenders K: NHG-standaard Diabetes mellitus type 2 (eerste herziening). Huisarts Wet 1999, 42:67-84.
• [24]Cromme PVM, Mulder JD, Rutten GEHM, Zuidweg J, Thomas S: NHG-standaard Diabetes mellitus type II. Huisarts Wet 1989, 32:15-8.
• [25]Struck J. Diagnostic use of prosomatostatin. US patent WO2012167887 A1. http://www.google.com/patents/WO2012167887A1?hl=nl&cl=en. Accessed 22 february 2015
• [26]Drion I, Kleefstra N, Landman GWD, Alkhalaf A, Struck J, Groenier KH, et al.: Plasma COOH-terminal proendothelin-1: a marker of fatal cardiovascular events, all-cause mortality, and new-onset albuminuria in type 2 diabetes? (ZODIAC-29). Diabetes Care 2012, 35:2354-8.
• [27]Riphagen IJ, Boertien WE, Alkhalaf A, Kleefstra N, Gansevoort RT, Groenier KH, et al.: Copeptin, a surrogate marker for arginine vasopressin, is associated with cardiovascular and all-cause mortality in patients with type 2 diabetes (ZODIAC-31). Diabetes Care 2013, 36:3201-7.
• [28]Landman GWD, van Dijk PR, Drion I, van Hateren KJJ, Struck J, Groenier KH, et al.: Mid-Regional fragment of pro-Adrenomedullin, new-onset Albuminuria, Cardiovascular and all-cause Mortality in Patients with Type 2 Diabetes (ZODIAC-30). Diabetes Care 2014, 37:839-45.
• [29]May S, Hosmer DW: A simplified method of calculating an overall goodness-of-fit test for the Cox proportional hazards model. Lifetime Data Anal 1998, 4:109-20.
• [30]Turman MA, O’Dorisio MS, O’Dorisio TM, Apple CA, Albers AR: Somatostatin expression in human renal cortex and mesangial cells. Regul Pept 1997, 68:15-21.
• [31]Díez-Marqués ML, García-Escribano C, Medina J, Boyano-Adanez MC, Arilla E, Torrecilla G, et al.: Effects of somatostatin on cultured human mesangial cells. Endocrinology 1995, 136:3444-51.
• [32]Flyvbjerg A: Role of growth hormone, insulin-like growth factors (IGFs) and IGF-binding proteins in the renal complications of diabetes. Kidney Int Suppl 1997, 60:S12-9.
• [33]Baldissera FG, Holst JJ, Jensen SL, Krarup T: Distribution and molecular forms of peptides containing somatostatin immunodeterminants in extracts from the entire gastrointestinal tract of man and pig. Biochim Biophys Acta 1985, 838:132-43.
• [34]Liddle RA, Ensinck JW: Cholecystokinin does not stimulate prosomatostatin-derived peptides in man. J Clin Endocrinol Metab 1990, 70:1403-7.